Bibliography

Scientific publications on Irreversible Electroporation

Stehling, M. K., Guenther, E., Klein, N. (2017) Irreversible Electroporation in Treatment of Prostate Cancer. Springer, Handbook of Electroporation.

Klein, N., Gunther, E., Zapf, S., El-Idrissi, R., Atta, J. and Stehling, M. (2017), Prostate cancer infiltrating the bladder sphincter successfully treated with Electrochemotherapy: a case report. Clin Case Rep. doi:10.1002/ccr3.1270.

Klein, N., Günther, E., Zapf, S., El-Idrissi, R., Rachor, S., & Stehling, M. (2016). Behandlung des Prostatakarzinoms mit Irreversibler Elektroporation (IRE). Deutsche Zeitschrift für Onkologie, 48(03), 111-116.

Savic, L. J., Chapiro, J., Hamm, B., Gebauer, B., & Collettini, F. (2016, August). Irreversible electroporation in interventional oncology: where we stand and where we go. In RöFo-Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren (Vol. 188, No. 08, pp. 735-745). © Georg Thieme Verlag KG.

Van de Bos, W., & De la Rosette, J. J. (2016). IRE for Prostate Cancer. In Interventional Urology (pp. 161-163). Springer International Publishing.

Rolong, A., Rubinsky, B., & Davalos, R. V. (2017). Tissue Ablation by Irreversible Electroporation. Handbook of Electroporation, 1-15.

Valerio, M., Dickinson, L., Ali, A., Ramachadran, N., Donaldson, I., Mccartan, N., ... & Emberton, M. (2017). Nanoknife Electroporation Ablation Trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer. The Journal of urology, 197(3), 647-654.

Wendler, J. J., Ganzer, R., Hadaschik, B., Blana, A., Henkel, T., Köhrmann, K. U., ... & Witzsch, U. (2017). Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage. World journal of urology, 35(1), 11-20.

Scheltema, M. J., Van Den Bos, W., de Bruin, D. M., Wijkstra, H., Laguna, M. P., de Reijke, T. M., & de la Rosette, J. J. (2016). Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial. BMC cancer, 16(1), 299.

Murray, K. S., Ehdaie, B., Musser, J., Mashni, J., Srimathveeravalli, G., Durack, J. C., ... & Coleman, J. A. (2016). Pilot study to assess safety and clinical outcomes of irreversible electroporation for partial gland ablation in men with prostate cancer. The Journal of urology, 196(3), 883-890.

Van den Bos, W., De Bruin, D. M., Jurhill, R. R., Savci-Heijink, C. D., Muller, B. G., Varkarakis, I. M., ... & de Reijke, T. M. (2016). The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World journal of urology, 34(5), 657-664.

Ting, F., Tran, M., Böhm, M., Siriwardana, A., Van Leeuwen, P. J., Haynes, A. M., ... & Stricker, P. D. (2016). Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate cancer and prostatic diseases, 19(1), 46-52.

Valerio, M., Ahmed, H. U., & Emberton, M. (2015). Focal therapy of prostate cancer using irreversible electroporation. Techniques in vascular and interventional radiology, 18(3), 147-152.

Tomihama, R. T., Günther, E., Kim, D., & Stehling, M. (2015). Irreversible electroporation treatment for prostate adenocarcinomas: a safety outcome study. Journal of Vascular and Interventional Radiology, 2(26), S121-S122.

Valerio, M., Stricker, P. D., Ahmed, H. U., Dickinson, L., Ponsky, L., Shnier, R., ... & Emberton, M. (2014). Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate cancer and prostatic diseases, 17(4), 343-347.

Fenner, A. (2014). Prostate cancer: irreversible electroporation is a safe and feasible option for focal therapy. Nature Reviews Urology, 11(11), 600-600.

Neal II, R. E., Rossmeisl Jr, J. H., Robertson, J. L., Arena, C. B., Davis, E. M., Singh, R. N., ... & Davalos, R. V. (2013). Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice. PloS one, 8(5), e64559.

Onik, G. (2014). Focal Therapy for Prostate Cancer Using Irreversible Electroporation. In Image Guided Prostate Cancer Treatments (pp. 235-241). Springer Berlin Heidelberg.

Neal, R. E., Kavnoudias, H., Rosenfeldt, F., Ou, R., Marron, J., Davalos, R. V., & Thomson, K. R. (2013, June). In Vivo Validation of Irreversible Electroporation Electric Field Threshold for Prostate Tissue. In ASME 2013 Summer Bioengineering Conference (pp. V01BT42A003-V01BT42A003). American Society of Mechanical Engineers.

Valerio, M., Dickinson, L., Ali, A., Ramachandran, N., Donaldson, I., Freeman, A., ... & Emberton, M. (2014). A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemporary clinical trials, 39(1), 57-65.

Onik, G., & Rubinsky, B. (2010). Irreversible electroporation: first patient experience focal therapy of prostate cancer. Irreversible Electroporation, 235-247.

Rubinsky, B. (2007). Irreversible electroporation in medicine. Technology in cancer research & treatment, 6(4), 255-259.

Rubinsky, B., Onik, G., & Mikus, P. (2007). Irreversible electroporation: a new ablation modality—clinical implications. Technology in cancer research & treatment, 6(1), 37-48.

Lee, E. W., Loh, C. T., & Kee, S. T. (2007). Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation. Technology in cancer research & treatment, 6(4), 287-293.

Onik, G., Mikus, P., & Rubinsky, B. (2007). Irreversible electroporation: implications for prostate ablation. Technology in cancer research & treatment, 6(4), 295-300.

Rubinsky, J., Onik, G., Mikus, P., & Rubinsky, B. (2008). Optimal parameters for the destruction of prostate cancer using irreversible electroporation. The Journal of urology, 180(6), 2668-2674.

Lee, E. W., Thai, S., & Kee, S. T. (2010). Irreversible electroporation: a novel image-guided cancer therapy. Gut and liver, 4(Suppl 1), S99.

Brausi, M. A., Giliberto, G. L., Simonini, G. L., Botticelli, L., & Di Gregorio, C. (2011). 960 Irreversible Electroporation (Ire), a Novel Technique for Focal Ablation of Prostate Cancer (Pca): Results of a Interim Pilot Safety Study in Low Risk Patients With Pca. European Urology Supplements, 10(2), 300.

Thomson, K. R., Cheung, W., Ellis, S. J., Federman, D., Kavnoudias, H., Loader-Oliver, D., ... & Haydon, A. (2011). Investigation of the safety of irreversible electroporation in humans. Journal of Vascular and Interventional Radiology, 22(5), 611-621.

Golberg, A., & Yarmush, M. L. (2013). Nonthermal irreversible electroporation: fundamentals, applications, and challenges. IEEE Transactions on biomedical Engineering, 60(3), 707-714.

Scheltema, Matthijs J., et al. (2018). Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World Journal of Urology (2018): 1-7.

Van den Bos, Willemien; Scheltema, Matthijs J.; Siriwardana, Amila R.; Kalsbeek, Anton M. F.; Thompson, James E.; Ting, Francis et al. (2017): Focal irreversible electroporation as primary treatment for localized prostate cancer. In: BJU international. DOI: 10.1111/bju.13983.

Van den Bos, Willemien, et al. "Focal irreversible electroporation as primary treatment for localized prostate cancer." BJU international 121.5 (2018): 716-724.

Scheltema, Matthijs J., et al. "Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio‐recurrent prostate cancer." BJU international 120 (2017): 51-58.

Scheltema, Matthijs, and Jean de la Rosette. "Irreversible Electroporation of Prostate Tumors." Irreversible Electroporation in Clinical Practice. Springer, Cham, 2018. 215-222.

Scheltema, Matthijs J., et al. "Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments." Diagnostic and Interventional Radiology 24.5 (2018): 268.

Guillaumier, Stephanie, et al. "A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer." European urology74.4 (2018): 422-429.

Scientific publications on transperineal 3D prostate biopsy

Crawford, E. D., Wilson, S. S., Torkko, K. C., Hirano, D., Stewart, J. S., Brammell, C., ... & Werahera, P. N. (2005). Clinical staging of prostate cancer: a computersimulated study of transperineal prostate biopsy. BJU international, 96(7), 999-1004.

Onik, G., Miessau, M., & Bostwick, D. G. (2009). Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. Journal of Clinical Oncology, 27(26), 4321-4326.

Walz, J., Graefen, M., Chun, F. K. H., Erbersdobler, A., Haese, A., Steuber, T., ... & Karakiewicz, P. I. (2006). High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. European urology, 50(3), 498-505.

Dominguez-Escrig, J. L., McCracken, S. R. C., & Greene, D. (2010). Beyond diagnosis: evolving prostate biopsy in the era of focal therapy. Prostate Cancer, 2011.

Galfano, A., Novara, G., Iafrate, M., Cosentino, M., Cavalleri, S., Artibani, W., & Ficarra, V. (2007). Prostate biopsy: the transperineal approach. eau-ebu update series, 5(6), 241-249.

Onik, G., Miessau, M., & Bostwick, D. G. (2009). Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. Journal of Clinical Oncology, 27(26), 4321-4326.

Onik, G., & Barzell, W. (2008). Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. In Urologic Oncology: Seminars and Original Investigations (Vol. 26, No. 5, pp. 506-510). Elsevier.

Onik, G., Miessau, M., & Bostwick, D. G. (2009). Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. Journal of Clinical Oncology, 27(26), 4321-4326.

Li, H., Yan, W., Zhou, Y., Ji, Z., & Chen, J. (2007). Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: report of 303 cases. Urology, 70(6), 1157-1161.

Tsivian, M., Kimura, M., Sun, L., Mouraviev, V., Mayes, J. M., & Polascik, T. J. (2010). Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU international, 105(8), 1089-1092.

Mouraviev, V., Mayes, J. M., Sun, L., Madden, J. F., Moul, J. W., & Polascik, T. J. (2007). Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer, 110(4), 906-910.

Mayes, J. M., Mouraviev, V., Sun, L., Tsivian, M., Madden, J. F., & Polascik, T. J. (2011, April). Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?. In Urologic Oncology: Seminars and Original Investigations (Vol. 29, No. 2, pp. 166-170). Elsevier.

Schulte, R. T., Wood, D. P., Daignault, S., Shah, R. B., & Wei, J. T. (2008). Utility of extended pattern prostate biopsies for tumor localization. Cancer, 113(7), 1559-1565.

Polascik, T. J., Mayes, J. M., Schroeck, F. R., Sun, L., Madden, J. F., Moul, J. W., & Mouraviev, V. (2009). Patient selection for hemiablative focal therapy of prostate cancer. Cancer, 115(10), 2104-2110.

Buyyounouski, M. K., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., Hanks, G. E., & Pollack, A. (2003). Positive prostate biopsy laterality and implications for staging. Urology, 62(2), 298-303.

Scales, C. D., Presti, J. C., Kane, C. J., Terris, M. K., Aronson, W. J., Amling, C. L., ... & SEARCH Database Study Group. (2007). Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy—results from the SEARCH database. The Journal of urology, 178(4), 1249-1252.

Tsivian, M., Moreira, D. M., Sun, L., Mouraviev, V., Kimura, M., Moul, J. W., & Polascik, T. J. (2012, February). Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. In Urologic Oncology: Seminars and Original Investigations (Vol. 30, No. 1, pp. 21-25). Elsevier.

Barzell, W. E., & Melamed, M. R. (2007). Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate—a 4-year experience. Urology, 70(6), S27-S35.

Sartor, A. O., Hricak, H., Wheeler, T. M., Coleman, J., Penson, D. F., Carroll, P. R., ... & Scardino, P. T. (2008). Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology, 72(6), S12-S24.

Watanabe, M., Hayashi, T., Tsushima, T., Irie, S., Kaneshige, T., & Kumon, H. (2005). Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection. International journal of urology, 12(11), 959-963.

Kawakami, S., Hyochi, N., Yonese, J., Yano, M., Fujii, Y., Kageyama, Y., ... & Kihara, K. (2006). Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. International journal of clinical oncology, 11(2), 127-132.

Numao, N., Kawakami, S., Yokoyama, M., Yonese, J., Arisawa, C., Ishikawa, Y., ... & Kihara, K. (2007). Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy. European urology, 52(6), 1663-1669.

Kawakami, S., Okuno, T., Yonese, J., Igari, T., Arai, G., Fujii, Y., ... & Kihara, K. (2007). Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. European urology, 51(3), 675-683.

Numao, N., Kawakami, S., Yonese, J., Koga, F., Saito, K., Fujii, Y., ... & Kihara, K. (2008). Threedimensional 26core biopsybased patient selection criteria for nervesparing radical prostatectomy. International journal of urology, 15(12), 1061-1066.

Arumainayagam, N., Ahmed, H. U., Moore, C. M., Freeman, A., Allen, C., Sohaib, S. A., ... & Emberton, M. (2013). Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology, 268(3), 761-769.

Dominguez-Escrig, J. L., McCracken, S. R. C., & Greene, D. (2010). Beyond diagnosis: evolving prostate biopsy in the era of focal therapy. Prostate Cancer, 2011.

Barqawi, A. B., Rove, K. O., Gholizadeh, S., O'donnell, C. I., Koul, H., & Crawford, E. D. (2011). The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. The Journal of urology, 186(1), 80-85.

Crawford, E. D., Rove, K. O., Barqawi, A. B., Maroni, P. D., Werahera, P. N., Baer, C. A., ... & La Rosa, F. G. (2013). Clinicalpathologic correlation between transperineal mapping biopsies of the prostate and threedimensional reconstruction of prostatectomy specimens. The Prostate, 73(7), 778-787. 

Scientific references for MRI and diagnostic imaging of the prostate

Dickinson, L., Ahmed, H. U., Allen, C., Barentsz, J. O., Carey, B., Futterer, J. J., ... & Persad, R. (2011). Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. European urology, 59(4), 477-494.

Villers, A., Marliere, F., Ouzzane, A., Puech, P., & Lemaître, L. (2012). MRI in addition to or as a substitute for prostate biopsy: the clinician's point of view. Diagnostic and interventional imaging, 93(4), 262-267.

Comet-Batlle, J., Vilanova-Busquets, J. C., Saladié-Roig, J. M., Gelabert-Mas, A., & Barceló-Vidal, C. (2003). The value of endorectal MRI in the early diagnosis of prostate cancer. European urology, 44(2), 201-208.

Kirkham, A. P., Emberton, M., & Allen, C. (2006). How good is MRI at detecting and characterising cancer within the prostate? European urology, 50(6), 1163-1175.

Hasumi, M., Suzuki, K., Taketomi, A., Matsui, H., Yamamoto, T., Ito, K., ... & Yamanaka, H. (2003). The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer research, 23(5b), 4223-4227.

Langer, D. L., van der Kwast, T. H., Evans, A. J., Trachtenberg, J., Wilson, B. C., & Haider, M. A. (2009). Prostate cancer detection with multiparametric MRI: Logistic regression analysis of quantitative T2, diffusionweighted imaging, and dynamic contrastenhanced MRI. Journal of magnetic resonance imaging, 30(2), 327-334.

Wysock, J. S., Mendhiratta, N., Zattoni, F., Meng, X., Bjurlin, M., Huang, W. C., ... & Taneja, S. S. (2016). Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12core biopsy results. BJU international, 118(4), 515-520.

Thompson, J. E., van Leeuwen, P. J., Moses, D., Shnier, R., Brenner, P., Delprado, W., ... & Stricker, P. D. (2016). The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. The Journal of urology, 195(5), 1428-1435.

Radtke, J. P., Schwab, C., Wolf, M. B., Freitag, M. T., Alt, C. D., Kesch, C., ... & Bonekamp, D. (2016). Multiparametric magnetic resonance imaging (MRI) and MRI–transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. European urology, 70(5), 846-853.

Fütterer, J. J., Briganti, A., De Visschere, P., Emberton, M., Giannarini, G., Kirkham, A., ... & Villers, A. (2015). Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. European urology, 68(6), 1045-1053.

Scheltema, Matthijs J., et al. "Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation." European urology focus (2017).

Faria, Rita, et al. "Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: a cost-effectiveness analysis based on the Prostate MR Imaging Study (PROMIS)." European urology 73.1 (2018): 23-30.

Moldovan, P., et al. "What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis." European Urology Supplements 17.2 (2018): e1727-e1728.

Panebianco, Valeria, et al. "Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer." European Urology Oncology (2018).

Venderink, Wulphert, et al. "Results of targeted biopsy in men with magnetic resonance imaging lesions classified equivocal, likely or highly likely to be clinically significant prostate cancer." European urology 73.3 (2018): 353-360.

Cantiello, F., et al. "Latest Evidence On The Role Of Multiparametric Magnetic Resonance Imaging In Active Surveillance For Insignificant Prostate Cancer: A Systematic Review." Anti-cancer agents in medicinal chemistry (2018).

Futterer, J.J.,et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol, 2015. 68: 1045. https://www.ncbi.nlm.nih.gov/pubmed/25656808